A Search Service for Abbreviation / Long Form

■検索結果 - 略語 : PD-1

検索条件

検索語：PD-1

検索方法：完全一致

主な研究分野:

結果

該当略語:2

(何れかを選択して該当結果を表示)

(出現頻度降順)

略語: PD-1

出現頻度: 7076

対応する展開形の数: 65

No.

展開形

主な研究分野

共起略語

PubMed/MEDLINE情報 (発表年, 題目)

programmed death-1

プログラムデスレセプタ-1

(6982回)

Neoplasms

新生物, 腫瘍

(2312回)

PD-L1(2317回)

CTLA-4(806回)

NSCLC(719回)

1997Activation-induced expression of human programmed death-1 gene in T-lymphocytes.

PDCD-1

(7回)

Neoplasms

新生物, 腫瘍

(2回)

MSI(2回)

ACT(1回)

BC(1回)

2015Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.

anti-PD-1 monotherapy

(5回)

Neoplasms

新生物, 腫瘍

(4回)

OS(3回)

RFS(3回)

ORR(2回)

2021Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.

programmed dead cell-1

(5回)

Medicine

医学, 医薬

(3回)

T1D(3回)

PD-L1(2回)

CD(1回)

2016PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

PD-L1 or programmed cell death-1

(5回)

Neoplasms

新生物, 腫瘍

(2回)

PD-L1(4回)

ADC(1回)

APACHE(1回)

2017PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1alpha.

death-protein 1

(4回)

Nuclear Medicine

核医学

(1回)

PD-L1(2回)

Ab(1回)

CTL(1回)

2019A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.

PD-1hi

(3回)

Microbiological Phenomena

(1回)

EC(1回)

FACS(1回)

FV(1回)

2018Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.

anti-PDCD1

(2回)

Neoplasms

新生物, 腫瘍

(1回)

B2M(1回)

FSP(1回)

MMR(1回)

2018High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.

protein death-1

(2回)

Immune System Diseases

(1回)

CTLA-4(1回)

ICB(1回)

2016PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients.

anti-PD-1 antibodies

(2回)

Liver Neoplasms

(1回)

LEN(2回)

DFS(1回)

HCC(1回)

2021Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.

PDCD1, CD279

(2回)

Pathology

病理学, 病態学

(1回)

ALDH1(1回)

AML(1回)

2017Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.

anti-program cell death -1

(2回)

Neoplasms

新生物, 腫瘍

(1回)

aNSCLC(1回)

BMI(1回)

BOR(1回)

2020PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.

anti-program death-1

(2回)

Neoplasms

新生物, 腫瘍

(1回)

RFS(2回)

NSCLC(1回)

OS(1回)

2016Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.

programmed cell death 1-positive

(2回)

Medicine

医学, 医薬

(1回)

ICOS(2回)

AUC(1回)

BCL6(1回)

2016[Detection of peripheral follicular helper T cells in rheumatoid arthritis].

anti-PD-L1/anti- programmed cell death 1

(1回)

Neoplasms

新生物, 腫瘍

(1回)

DFS(1回)

LNMs(1回)

PD-L1(1回)

2018Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.

anti-PD-1 was used to activate or block the programmed death

(1回)

Medicine

医学, 医薬

(1回)

CD28(1回)

ELISA(1回)

IFN-gamma(1回)

2019PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.

Programmed death receptor 1 antibody

(1回)

(0回)

BCC(1回)

cSCC(1回)

Hh(1回)

2024Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options.

Programmed death-ligand 1 receptor

(1回)

Medicine

医学, 医薬

(1回)

AAV(1回)

irAEs(1回)

PD-L1(1回)

2022Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.

Programmed necrosis factor 1

(1回)

Allergy and Immunology

アレルギー・免疫

(1回)

AP(1回)

2021PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis.

Pembrolizumab: a novel antiprogrammed death 1

(1回)

Pharmacy

薬学

(1回)

2015Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.